Here's Why 2022 May Be Even Bigger for Moderna Than 2021

Countries have ordered hundreds of millions of coronavirus vaccine doses over the past several months. And people around the world have flocked to vaccination centers to get a jab. That has benefited one of today's leaders: Moderna (NASDAQ: MRNA). In this Motley Fool Live video recorded on May 28, 2021, Healthcare and Cannabis Bureau Editor and Analyst Olivia Zitkus and Fool.com contributor Adria Cimino discuss this year's revenue prospects for Moderna -- and how the need for its coronavirus vaccine may be even greater in 2022.

Continue reading

Source Fool.com